查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485042

活性藥物成分 CDMO 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按分子類型、合成、藥物類型、工作流程、應用、地區和競爭細分，2019-2029F

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Molecule Type, By Synthesis, By Drug Type, By Workflow, By Application, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球活性藥物成分CDMO 市場估值為919.8 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為6.10%。 。這些挑戰包括需要在保持高品質標準的同時降低成本、需要經濟實惠的設備以及將創新產品快速推向市場的壓力。為了應對這些挑戰，合約開發和製造組織 (CDMO) 已成為製藥公司的重要合作夥伴。 CDMO 與製藥公司合作開發和生產藥物，無需對基礎設施或資源進行額外投資。透過將原料藥製造外包給 CDMO，製藥公司可以專注於其研究和行銷等核心能力，同時利用 CDMO 在製造和開發方面的專業知識和能力。這種合作夥伴關係模式使製藥公司能夠更快、更具成本效益地將新產品推向市場。製藥 CDMO 的主要職責之一是處理原料藥的外包。這涉及根據製藥公司提供的規格生產活性藥物成分（API）或藥物中間體。 CDMO 利用其在化學和製造方面的專業設施和專業知識來生產符合監管標準的高品質原料藥。

市場概況
預測期 2025-2029
2023 年市場規模 919.8億美元
2029 年市場規模 1307億美元
2024-2029 年複合年成長率 6.10%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

除了生產原料藥外，製藥 CDMO 在創新和開發過程中也發揮著至關重要的作用。 CDMO 在預生產階段與製藥公司密切合作，開發配方、進行可行性研究和最佳化製程。這種合作確保最終產品在功效、安全性和品質方面滿足所需的規格。製藥公司和 CDMO 之間的合作是互惠互利的。製藥公司受益於 CDMO 的最先進設施、專業知識和可擴展的製造能力，使他們能夠更快、更有效地將新藥推向市場。另一方面，CDMO 受益於與製藥公司的長期合作夥伴關係，這提供了穩定的業務和成長機會。製藥 CDMO 為醫療保健行業的積極成長做出了重大貢獻。透過使製藥公司能夠在處理製造和開發過程的同時專注於創新和行銷，CDMO 在加快藥物發現和開發的步伐方面發揮著至關重要的作用。這反過來又導致了新的和改進的療法的引入，以解決未滿足的醫療需求並改善患者的治療結果。製藥 CDMO 已成為製藥公司不可或缺的合作夥伴，提供一系列服務，包括原料藥製造、配方開發和製程最佳化。透過利用 CDMO 的專業知識和能力，製藥公司可以簡化營運、降低成本並更快地將創新產品推向市場。製藥公司和 CDMO 之間的合作夥伴關係對於推動醫療保健產業的積極成長和推動全球患者新療法的開發至關重要。

主要市場促進因素

定製藥物開發的需求不斷增加

不斷發展的生物製藥產業

複雜藥物分子的增加

主要市場挑戰

監理複雜性

品質控制和合規性

主要市場趨勢

細胞和基因療法

細分市場洞察

綜合見解

藥物類型見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型（小分子、大分子）
    • 透過合成（生物技術、合成）
    • 依藥物類型（創新藥、學名藥）
    • 按工作流程（臨床、商業）
    • 按應用（心臟病學、腫瘤學、眼科、神經病學、骨科、其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2023)
  • 市場地圖
  • 依分子類型
  • 透過合成
  • 依藥物類型
  • 按工作流程
  • 按申請
  • 按地區

第 6 章：北美活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型
    • 透過合成
    • 依藥物類型
    • 按工作流程
    • 按申請
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型
    • 透過合成
    • 依藥物類型
    • 按工作流程
    • 按申請
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型
    • 透過合成
    • 依藥物類型
    • 按工作流程
    • 按申請
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型
    • 透過合成
    • 依藥物類型
    • 按工作流程
    • 按申請
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲活性藥物成分 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型
    • 透過合成
    • 依藥物類型
    • 按工作流程
    • 按申請
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球活性藥物成分 CDMO 市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • Cambrex Corporation
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Corden Pharma International GmbH
  • Samsung Biologics Co., Ltd.
  • Lonza Group Ltd.
  • Siegfried Holding AG
  • Piramal Pharma Limited
  • AbbVie Inc.
  • Catalent, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21111

Global Active Pharmaceutical Ingredients CDMO Market was valued at USD 91.98 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.10% through 2029. The pharmaceutical industry faces numerous challenges in the manufacturing of drug substances and the development of pharmaceutical applications. These challenges include the need to reduce costs while maintaining high-quality standards, the requirement for affordable equipment, and the pressure to bring innovative products to market quickly. In response to these challenges, Contract Development and Manufacturing Organizations (CDMOs) have emerged as key partners for pharmaceutical companies. CDMOs collaborate with pharmaceutical companies to develop and manufacture drugs without the need for additional investment in infrastructure or resources. By outsourcing drug substance manufacturing to CDMOs, pharmaceutical companies can focus on their core competencies such as research and marketing, while leveraging the expertise and capabilities of CDMOs in manufacturing and development. This partnership model allows pharmaceutical companies to bring new products to market faster and more cost-effectively. One of the primary roles of Pharmaceutical CDMOs is to handle the outsourcing of drug substances. This involves the production of active pharmaceutical ingredients (APIs) or drug intermediates according to the specifications provided by the pharmaceutical companies. CDMOs utilize their specialized facilities and expertise in chemistry and manufacturing to produce high-quality drug substances that meet regulatory standards.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 91.98 Billion
Market Size 2029USD 130.70 Billion
CAGR 2024-20296.10%
Fastest Growing SegmentOncology
Largest MarketNorth America

In addition to manufacturing drug substances, Pharmaceutical CDMOs also play a crucial role in the innovation and development process. CDMOs work closely with pharmaceutical companies during the pre-manufacturing phase to develop formulations, conduct feasibility studies, and optimize processes. This collaboration ensures that the final product meets the desired specifications in terms of efficacy, safety, and quality. The partnership between pharmaceutical companies and CDMOs is mutually beneficial. Pharmaceutical companies benefit from access to CDMO's state-of-the-art facilities, specialized expertise, and scalable manufacturing capabilities, allowing them to bring new drugs to market faster and more efficiently. On the other hand, CDMOs benefit from long-term partnerships with pharmaceutical companies, which provide a steady stream of business and opportunities for growth. Pharmaceutical CDMOs contribute significantly to the positive growth of the healthcare industry. By enabling pharmaceutical companies to focus on innovation and marketing while handling the manufacturing and development process, CDMOs play a vital role in accelerating the pace of drug discovery and development. This, in turn, leads to the introduction of new and improved therapies that address unmet medical needs and improve patient outcomes. Pharmaceutical CDMOs have become integral partners for pharmaceutical companies, offering a range of services including drug substance manufacturing, formulation development, and process optimization. By leveraging the expertise and capabilities of CDMOs, pharmaceutical companies can streamline their operations, reduce costs, and bring innovative products to market faster. The collaborative partnership between pharmaceutical companies and CDMOs is essential for driving positive growth in the healthcare industry and advancing the development of new therapies for patients worldwide.

Key Market Drivers

Increasing Demand for Customized Drug Development

Pharmaceutical companies often require specialized expertise and technologies to develop and manufacture customized drugs, which may include complex small molecules, biologics, high-potency compounds, or novel formulations. CDMOs with a focus on customization have the necessary knowledge and infrastructure to meet these specific needs, making them invaluable partners for pharmaceutical companies. Customized drug development often involves innovative and unique approaches to drug design and manufacturing. CDMOs can provide pharmaceutical companies with the resources and capabilities to expedite drug development processes, reducing time-to-market for new drugs.

Customized drug development can be resource-intensive, requiring substantial investments in research and development (R&D). Outsourcing to CDMOs allows pharmaceutical companies to access specialized capabilities without the need for substantial in-house investments, thereby reducing overall R&D costs. CDMOs offer scalable manufacturing solutions, allowing pharmaceutical companies to adjust production volumes as needed. This scalability is crucial for customized drugs, as demand can vary widely, from small-batch clinical trials to large-scale commercial production. Customized drug development often involves high levels of technical risk due to the unique nature of the compounds or formulations. By partnering with experienced CDMOs, pharmaceutical companies can mitigate these risks by leveraging the CDMO's expertise and track record in handling similar challenges. CDMOs specializing in customized drug development are well-versed in navigating complex regulatory requirements. They can help ensure that the customized drugs meet all regulatory standards, which is crucial for gaining approval and commercialization.

Growing Biopharmaceuticals Sector

Biopharmaceuticals, which include biologics like monoclonal antibodies, vaccines, and gene therapies, require specialized manufacturing processes. CDMOs with expertise in bioprocessing and biomanufacturing are in high demand to assist pharmaceutical companies in producing these complex and large-molecule drugs. Many pharmaceutical companies, especially smaller or newer entrants in the industry, may not have the in-house expertise or infrastructure for biologics development and manufacturing. They turn to CDMOs to access the necessary resources and skills. Building and maintaining biopharmaceutical manufacturing facilities can be incredibly expensive and time-consuming. Outsourcing to CDMOs allows pharmaceutical companies to reduce capital expenditures, minimize operational costs, and achieve cost-efficiency in biologics production.

The biopharmaceutical industry often faces fluctuations in demand, particularly for biologics with variable production requirements. CDMOs offer the flexibility to scale up or down production volumes as needed, optimizing resource utilization for pharmaceutical companies. Regulatory agencies have stringent requirements for the manufacturing and quality control of biologics. Established CDMOs have a track record of compliance with these regulations, giving pharmaceutical companies confidence in the quality and safety of their biopharmaceutical products. CDMOs specializing in biologics can expedite the drug development and manufacturing process. Their expertise, infrastructure, and streamlined operations can significantly reduce the time it takes to bring biopharmaceutical products to market, enabling pharmaceutical companies to capture opportunities more quickly.

Rise in Complex Drug Molecules

Complex drug molecules, which include high-potency APIs, biologics, and advanced formulations, require specialized knowledge and capabilities for their development and manufacturing. CDMOs with expertise in handling complex drug molecules become essential partners for pharmaceutical companies seeking to navigate the challenges of these compounds. Complex drug molecules often necessitate the use of advanced technologies and sophisticated manufacturing processes. CDMOs invest in state-of-the-art equipment and infrastructure to accommodate these requirements, making them well-suited to support the development and production of complex drugs. Developing and manufacturing complex drug molecules can be associated with higher technical and regulatory risks. Pharmaceutical companies can mitigate these risks by partnering with experienced CDMOs that have a proven track record of successfully handling complex compounds.

Complex drug molecules frequently face rigorous regulatory scrutiny due to their unique characteristics. CDMOs specializing in complex compounds have established quality assurance systems and compliance protocols to ensure that the products meet regulatory requirements. Developing and maintaining the infrastructure for complex drug manufacturing can be prohibitively expensive. By outsourcing to CDMOs, pharmaceutical companies can reduce capital investments, minimize operational costs, and achieve cost-efficiency in the production of complex drug molecules. CDMOs can tailor their services to the specific needs of pharmaceutical companies developing complex drugs. This customization ensures that the manufacturing processes are optimized for the unique properties and requirements of each compound.

Key Market Challenges

Regulatory Complexities

The pharmaceutical industry is highly regulated, and CDMOs must adhere to a myriad of stringent quality and safety standards. Compliance with these regulations often requires significant investments in infrastructure, personnel, and documentation. The associated compliance costs can reduce profit margins and make it challenging for CDMOs to offer competitive pricing. Regulatory approvals and compliance checks can introduce delays into the drug development and manufacturing process. CDMOs may face prolonged approval processes, inspections, and audits, which can impact project timelines. Pharmaceutical companies may seek faster alternatives, such as in-house manufacturing, to mitigate these delays. Meeting regulatory requirements demands substantial resources, including specialized personnel and extensive documentation. Smaller or newer CDMOs may struggle to allocate the necessary resources, hindering their ability to compete effectively in the market.

The pharmaceutical regulatory landscape varies from one region to another, with differences in standards, documentation, and inspection requirements. CDMOs operating in multiple countries must navigate this complex global regulatory environment, which can be both time-consuming and costly. Regulatory non-compliance can have severe consequences, including product recalls, legal penalties, and damage to a CDMO's reputation. The fear of non-compliance may deter pharmaceutical companies from partnering with CDMOs, especially those without a strong track record of regulatory adherence. Regulatory agencies demand extensive documentation of manufacturing processes, quality control, and product testing. Maintaining accurate and comprehensive records is resource-intensive and can divert CDMO staff from core activities.

Quality Control and Compliance

Ensuring quality and compliance requires significant investments in infrastructure, personnel, and quality control processes. CDMOs must allocate substantial resources to maintain compliance, which can increase operational costs and reduce profit margins. Quality assurance and compliance procedures often involve meticulous documentation, quality control checks, and validation processes. These activities can be time-consuming and may introduce delays into project timelines, potentially frustrating pharmaceutical clients. Regulatory authorities impose strict standards on the pharmaceutical industry to ensure product safety and efficacy. CDMOs must continuously monitor and adapt to these evolving regulations, which can be complex and demanding.

Non-compliance with quality and regulatory standards can have severe consequences, including product recalls, regulatory fines, and reputational damage. The fear of non-compliance can make pharmaceutical companies cautious about partnering with CDMOs that do not have a strong track record in this regard. Maintaining comprehensive documentation for every aspect of drug development and manufacturing is a fundamental requirement for compliance. The extensive paperwork and record-keeping can be resource-intensive and divert CDMO staff from core tasks. The global pharmaceutical market encompasses a range of regulatory bodies, each with its own set of requirements. CDMOs operating on a global scale must navigate the varying compliance standards of different regions, adding complexity to their operations.

Key Market Trends

Cell and Gene Therapies

Cell and gene therapies require highly specialized expertise and infrastructure for development and manufacturing. CDMOs with capabilities in cell culture, viral vector production, and gene editing technologies are in high demand to support these innovative therapies. CDMOs are investing heavily in cutting-edge technologies and facilities tailored for cell and gene therapy production. This includes state-of-the-art cleanroom environments, bioreactors, and cryopreservation systems designed to meet the unique requirements of these therapies. The growth in demand for cell and gene therapies has prompted CDMOs to expand their manufacturing capacity in this sector. This includes constructing dedicated facilities to handle the specialized processes involved in the production of these therapies.

The regulatory landscape for cell and gene therapies is complex and evolving. CDMOs specializing in these therapies possess in-depth knowledge of regulatory requirements, helping pharmaceutical companies navigate the approval process and ensure compliance. Cell and gene therapies come with inherent technical and regulatory risks. Pharmaceutical companies mitigate these risks by partnering with CDMOs experienced in managing the complexities and challenges associated with these therapies. The demand for cell and gene therapies extends worldwide, necessitating a global presence for CDMOs to provide access to diverse markets and ensure compliance with local regulatory authorities.

Segmental Insights

Synthesis Insights

Based on Synthesis, the biotech emerged as the fastest growing segment in the Global Active Pharmaceutical Ingredients CDMO Market in 2023. The biotech sector is increasingly focused on rare diseases, leading to a growing demand for CDMOs specializing in the development and manufacturing of orphan drugs. These drugs often require unique formulations and production processes. As research in neurodegenerative disorders like Alzheimer's and Parkinson's disease advances, CDMOs are providing support for the development of innovative therapies targeting these conditions. This segment is poised for growth as more therapies progress through clinical trials. The development of vaccines, antiviral drugs, and treatments for infectious diseases remains a critical area of biotech research. CDMOs are contributing to the manufacturing of vaccines and therapies for infectious diseases, particularly in response to global health crises like pandemics.

Drug Type Insights

Based on Drug Type, the generics emerged as the dominating segment in the Global Active Pharmaceutical Ingredients CDMO Market during forecast period. Generic drugs are typically produced at a lower cost compared to their branded counterparts. CDMOs specializing in generics can leverage efficient and cost-effective manufacturing processes to meet the high demand for these products. The rising demand for generic drugs, driven by the need for affordable healthcare solutions, presents growth opportunities for CDMOs. As pharmaceutical companies seek to expand their generic drug portfolios, they often turn to CDMOs to access cost-efficient manufacturing capabilities. Generic drugs encompass a wide range of therapeutic categories, including cardiovascular, central nervous system, and respiratory medications. This diversity offers CDMOs opportunities to work on a variety of drug formulations and compounds.

Some generic drugs, particularly complex generics such as biosimilars and specialty generics, require advanced manufacturing technologies and expertise. CDMOs with capabilities in bioprocessing, sterile manufacturing, and complex dosage forms are in demand to support the development and production of these products. Ensuring regulatory compliance is crucial in the generic drug industry. CDMOs with a strong track record of meeting regulatory standards and navigating the complexities of abbreviated new drug applications (ANDAs) are sought after by pharmaceutical companies. The global reach of generic drugs creates opportunities for CDMOs with a presence in multiple regions. These CDMOs can help pharmaceutical companies access diverse markets and meet local regulatory requirements.

Regional Insights

Based on region, North America dominated the Global Active Pharmaceutical Ingredients CDMO Market in 2023. This is primarily due to North America, particularly the United States, represents one of the largest pharmaceutical markets in the world. The region's prominence in pharmaceutical research, development, and manufacturing makes it a primary driver of global API CDMO market growth. Pharmaceutical companies in North America increasingly rely on CDMOs to outsource various stages of drug development and manufacturing. The growing demand for CDMO services is driven by factors such as cost-efficiency, regulatory expertise, and access to specialized technologies. North America is a global hub for biotechnology and pharmaceutical research and innovation. This concentration of biotech and pharma companies creates a thriving ecosystem for CDMOs to collaborate and provide essential support in developing novel drug compounds.

North America is a leader in the development of biologics and complex molecules, including monoclonal antibodies, gene therapies, and biosimilars. CDMOs with expertise in these areas are well-positioned to serve the region's biopharmaceutical companies. North America has stringent regulatory requirements for drug development and manufacturing. CDMOs operating in the region must maintain a deep understanding of regulatory standards and demonstrate compliance, making them valuable partners for pharmaceutical companies navigating this complex landscape. North American pharmaceutical companies often form strategic alliances with CDMOs to expedite drug development and access specialized expertise. These collaborations drive growth in the Active Pharmaceutical Ingredients CDMO market as they tap into the region's extensive pharmaceutical infrastructure.

Key Market Players

Cambrex Corporation

Thermo Fisher Scientific, Inc.

Recipharm AB

Corden Pharma International GmbH

Samsung Biologics Co., Ltd.

Lonza Group Ltd.

Siegfried Holding AG

Piramal Pharma Limited

AbbVie Inc.

Catalent, Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

    Small Molecule Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

    Biotech Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

    Innovative Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

    Clinical Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

    Cardiology Oncology Ophthalmology Neurology Orthopedic Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 5.2.2. By Synthesis (Biotech, Synthetic)
    • 5.2.3. By Drug Type (Innovative, Generics)
    • 5.2.4. By Workflow (Clinical, Commercial)
    • 5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.7. By Company (2023)
  • 5.3. Market Map
  • 5.3.1 By Molecule Type
  • 5.3.2 By Synthesis
  • 5.3.3 By Drug Type
  • 5.3.4 By Workflow
  • 5.3.5 By Application
  • 5.3.6 By Region

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 6.2.2. By Synthesis (Biotech, Synthetic)
    • 6.2.3. By Drug Type (Innovative, Generics)
    • 6.2.4. By Workflow (Clinical, Commercial)
    • 6.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Molecule Type
        • 6.3.1.2.2. By Synthesis
        • 6.3.1.2.3. By Drug Type
        • 6.3.1.2.4. By Workflow
        • 6.3.1.2.5. By Application
    • 6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Molecule Type
        • 6.3.2.2.2. By Synthesis
        • 6.3.2.2.3. By Drug Type
        • 6.3.2.2.4. By Workflow
        • 6.3.2.2.5. By Application
    • 6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Molecule Type
        • 6.3.3.2.2. By Synthesis
        • 6.3.3.2.3. By Drug Type
        • 6.3.3.2.4. By Workflow
        • 6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 7.2.2. By Synthesis (Biotech, Synthetic)
    • 7.2.3. By Drug Type (Innovative, Generics)
    • 7.2.4. By Workflow (Clinical, Commercial)
    • 7.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Molecule Type
        • 7.3.1.2.2. By Synthesis
        • 7.3.1.2.3. By Drug Type
        • 7.3.1.2.4. By Workflow
        • 7.3.1.2.5. By Application
    • 7.3.2. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Molecule Type
        • 7.3.2.2.2. By Synthesis
        • 7.3.2.2.3. By Drug Type
        • 7.3.2.2.4. By Workflow
        • 7.3.2.2.5. By Application
    • 7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Molecule Type
        • 7.3.3.2.2. By Synthesis
        • 7.3.3.2.3. By Drug Type
        • 7.3.3.2.4. By Workflow
        • 7.3.3.2.5. By Application
    • 7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Molecule Type
        • 7.3.4.2.2. By Synthesis
        • 7.3.4.2.3. By Drug Type
        • 7.3.4.2.4. By Workflow
        • 7.3.4.2.5. By Application
    • 7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Molecule Type
        • 7.3.5.2.2. By Synthesis
        • 7.3.5.2.3. By Drug Type
        • 7.3.5.2.4. By Workflow
        • 7.3.5.2.5. By Application

8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 8.2.2. By Synthesis (Biotech, Synthetic)
    • 8.2.3. By Drug Type (Innovative, Generics)
    • 8.2.4. By Workflow (Clinical, Commercial)
    • 8.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Molecule Type
        • 8.3.1.2.2. By Synthesis
        • 8.3.1.2.3. By Drug Type
        • 8.3.1.2.4. By Workflow
        • 8.3.1.2.5. By Application
    • 8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Molecule Type
        • 8.3.2.2.2. By Synthesis
        • 8.3.2.2.3. By Drug Type
        • 8.3.2.2.4. By Workflow
        • 8.3.2.2.5. By Application
    • 8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Molecule Type
        • 8.3.3.2.2. By Synthesis
        • 8.3.3.2.3. By Drug Type
        • 8.3.3.2.4. By Workflow
        • 8.3.3.2.5. By Application
    • 8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Molecule Type
        • 8.3.4.2.2. By Synthesis
        • 8.3.4.2.3. By Drug Type
        • 8.3.4.2.4. By Workflow
        • 8.3.4.2.5. By Application
    • 8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Molecule Type
        • 8.3.5.2.2. By Synthesis
        • 8.3.5.2.3. By Drug Type
        • 8.3.5.2.4. By Workflow
        • 8.3.5.2.5. By Application

9. South America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 9.2.2. By Synthesis (Biotech, Synthetic)
    • 9.2.3. By Drug Type (Innovative, Generics)
    • 9.2.4. By Workflow (Clinical, Commercial)
    • 9.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Molecule Type
        • 9.3.1.2.2. By Synthesis
        • 9.3.1.2.3. By Drug Type
        • 9.3.1.2.4. By Workflow
        • 9.3.1.2.5. By Application
    • 9.3.2. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Molecule Type
        • 9.3.2.2.2. By Synthesis
        • 9.3.2.2.3. By Drug Type
        • 9.3.2.2.4. By Workflow
        • 9.3.2.2.5. By Application
    • 9.3.3. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Molecule Type
        • 9.3.3.2.2. By Synthesis
        • 9.3.3.2.3. By Drug Type
        • 9.3.3.2.4. By Workflow
        • 9.3.3.2.5. By Application

10. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 10.2.2. By Synthesis (Biotech, Synthetic)
    • 10.2.3. By Drug Type (Innovative, Generics)
    • 10.2.4. By Workflow (Clinical, Commercial)
    • 10.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Molecule Type
        • 10.3.1.2.2. By Synthesis
        • 10.3.1.2.3. By Drug Type
        • 10.3.1.2.4. By Workflow
        • 10.3.1.2.5. By Application
    • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Molecule Type
        • 10.3.2.2.2. By Synthesis
        • 10.3.2.2.3. By Drug Type
        • 10.3.2.2.4. By Workflow
        • 10.3.2.2.5. By Application
    • 10.3.3. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Molecule Type
        • 10.3.3.2.2. By Synthesis
        • 10.3.3.2.3. By Drug Type
        • 10.3.3.2.4. By Workflow
        • 10.3.3.2.5. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cambrex Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Recipharm AB
  • 15.4. Corden Pharma International GmbH
  • 15.5. Samsung Biologics Co., Ltd.
  • 15.6. Lonza Group Ltd.
  • 15.7. Siegfried Holding AG
  • 15.8. Piramal Pharma Limited
  • 15.9. AbbVie Inc.
  • 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer